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Phosphoinositide-specific phospholipase C is an effector mole-
cule in the signal transduction process. It generates two sec-
ond messengers, inositol-1,4,5-trisphosphate and diacylglycer-
ol from phosphatidylinositol 4,5-bisphosphate. Currently, thir-
teen mammal PLC isozymes have been identified, and they are 
divided into six groups: PLC-β, -γ, -δ, -ε, -ζ and -η. Sequence 
analysis studies demonstrated that each isozyme has more 
than one alternative splicing variant. PLC isozymes contain the 
X and Y domains that are responsible for catalytic activity. 
Several other domains including the PH domain, the C2 do-
main and EF hand motifs are involved in various biological 
functions of PLC isozymes as signaling proteins. The dis-
tribution of PLC isozymes is tissue and organ specific. Recent 
studies on isolated cells and knockout mice depleted of PLC 
isozymes have revealed their distinct phenotypes. Given the 
specificity in distribution and cellular localization, it is clear 
that each PLC isozyme bears a unique function in the modu-
lation of physiological responses. In this review, we discuss 
the structural organization, enzymatic properties and molec-
ular diversity of PLC splicing variants and study functional and 
physiological roles of each isozyme. [BMB reports 2008; 41(6): 
415-434]
INTRODUCTION
Phosphoinositide-specific phospholipase C (PLC) hydrolyzes 
phosphatidylinositol 4,5-bisphosphate (PIP2) to generate two 
second messengers: diacylglycerol (DAG) and inositol 1,4,5-tri-
sphosphate (IP3). DAG and IP3 initiate further signal transduction 
pathways through activation of protein kinase C (PKC) and intra-
cellular calcium release (1-3; Fig. 1a). 
    The first evidence of PLC activity was suggested by Hokin et 
al. in 1953 who reported specific hydrolysis of phospholipids 
in pigeon’s pancreas slices after cholinergic stimulation (4). 
The authors showed that the enhanced turnover of phosphor-
ylinositol groups of phosphatidylinositol occurred in cells as a 
response to a variety of stimuli. In 1983, Streb et al. demon-
strated that IP3 generated from PIP2 hydrolysis is responsible 
for mobilization of intracellular calcium in the pancreatic aci-
nar cells (5). Takenawa et al. purified the first PLC with a mo-
lecular weight of 68 kDa in 1981 (6). Subsequently, a number 
of PLCs of different molecular masses, isoelectric points and 
calcium dependency have been identified in several tissues. In 
the late 80 s, three PLC isozymes, namely PLC-γ, -β, and -δ, 
were isolated and their cDNA sequences were obtained (7). 
Since then, multiple types of PLC were found from various tis-
sues using either an RT-PCR method by specifically designed 
primers or a screening method using low stringency hybrid-
ization with probes made from the conserved domain X or Y. 
So far, 13 PLC isozymes have been identified in different 
mammalian tissues and they belong to six different subtypes. 
    Identification of PLC isozymes, PLC-ε and PLC-η, has 
changed our understanding of the relations between receptor 
tyrosine kinase (RTK)-PLC-γ and G protein-coupled receptor 
(GPCR)- PLC-β (Fig. 1b). Little is known about functions, rela-
tions and hierarchy of PLC isozymes. In this review, we discuss 
the questions of structural organization, enzymatic properties 
and molecular diversity of splicing variants of PLC isozymes in 
relation to their function and physiological significance. 
Structure of PLCs
Catalytic X and Y domains
Two highly conserved amino acid regions in PLC isozymes are 
the X and Y domains, which are located between EF-hand mo-
tifs and C2 domain. The domains are composed of alternating 
α-helices and β-strands and resemble incomplete triose phos-
phate isomerase (TIM) α /β-barrel (8). Crystallographic analysis 
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Fig. 1. Activation and function of various PLC isozymes. A) Phos-
pholipase-dependent PIP2 hydrolysis. PLC catalyzes the hydrolysis of 
PIP2, a member of membrane phospholipids. Two products, diac-
ylglycerol (DAG) and IP3 induce the activation of PKC and intra-
cellular Ca2＋ release, respectively. B) PLC related signaling pathway. 
Various extracellular signals stimulate hydrolysis of phosphatidylino-
sitol 4,5-bisphosphate (PIP2) by phosphoinositide-specific phospholi-
pase C (PLC). PLC hydrolyzes PIP2 to two important second mes-
sengers, diacylglycerol and inositol 1,4,5-trisphosphate (IP3). These 
two second messengers lead to the activation of several protein kin-
ase C (PKC) isoforms and the release of calcium from intracellular 
stores, respectively. PLC-β subtypes are activated by GPCR through 
several mechanisms. Pertusis toxin (PTX)-insensitive heterotrimeric
Gq family proteins (Gq, G11, G14, G15 and G16) activate PLC-β sub-
types via GTP-loaded Gα subunits. PLC-β subtypes are also acti-
vated by Gβγ subunits liberated from PTX-sensitive Gi family proteins.
Various growth factors such as platelet-derived growth factor (PDGF), 
epidermal growth factor (EGF), and nerve growth factor (NGF) can
activate PLC-γ isozymes. Upon growth factor stimulation, PLC-γ is 
recruited to activated growth factor receptors via SH2 domain-phos-
photyrosine interaction and then subjected to phosphorylation by re-
ceptor tyrosine kinases. PLC-ε can be activated by both GPCR and 
RTK activation with distinct activation mechanism. The activation 
mechanism for PLC-δ, η, ζ remains to be revealed. 
revealed that histidine residue functions as a general base lead-
ing to formation of 1,2-cyclic inositol 4,5-bisphosphate (9). 
Ca2＋ ions are required for lowering the pKa and promoting the 
nucleophilic attack on 1-phosphate. The following stabilization 
of the cyclic phosphate intermediate at the active site produces 
acyclic product (10). Catalytic residues are highly conserved in 
all eukaryotic PLC isozymes. Based on structural analysis of 
PLC-δ1, it has been suggested that Lys438, Lys440, Ser522 and 
Arg549 residues are present at the active site which are im-
plicated in interactions with 4- or 5-phosphate of the substrate 
headgroup (9, 11). Preferential hydrolysis of PIP2 has been at-
tributed to a positive charge at 549 position of PLC-δ1, which is 
conserved in the eukaryotic PLC catalytic core, This finding is 
supported by the fact that replacement of a charged residue 
causes suppression of PIP2 hydrolysis but not of PI (12).
PH domain
It has been shown that the PH domain in PLC-δ1 binds PIP2 
and advances the access of PLC-δ1 onto the membrane surface 
(13). The PH domain of PLC-β2 and PLC-β3 binds specifically 
to the heterotrimeric G protein subunit, Gβγ (14). The domain 
also mediates interactions with PIP3, which is required for 
PI3K-dependent PLC-γ1 translocation and activation (15). 
PLC-γ1 and γ2 contain an additional PH domain which is split 
by two tandem Src homology 2 (SH2) and a Src homology 3 
(SH3) domains. The C-terminal half of the PLC-γ split PH do-
main has been implicated to interact directly with the TRPC3 
calcium channel, thereby providing a direct coupling mecha-
nism between PLC-γ and agonist-induced calcium entry (16). 
C2 domain and EF-hands 
The C2 domain of PLC-δ1 possesses three to four Ca2＋ binding 
sites (8). Calcium ions bind to the C2 domain and enhance the 
enzymatic activity of PLC-δ1 by forming an enzyme-phosphati-
dylserine-Ca2＋ ternary complex. EF-hand motifs are helix-turn- 
helix structural domains which bind Ca2＋ ions. It was shown 
that the deletion of EF-hand motifs of PLC-δ1 resulted in a de-
crease in PLC activity in a Ca2＋-independent manner (17, 18). 
Although the EF-hand motif of PLC isozyme may have an im-
portant regulatory function, currently there is no strong evidence 
to support the notion that EF-hand motifs bind to metal ions.
Tissue distribution of PLCs
Thirteen mammalian PLC isozymes have been identified, so far 
in various tissues and cell types. Analysis of expressed se-
quence tags (EST) allows a systematic search of gene expression. 
We used EST database in NCBI Unigene, (http://www.ncbi.nlm. 
nih.gov/sites/entrez?db=unigene) to study the tissue distri-
bution of PLC isozymes and to analyze their mRNA expression. 
We found that PLC-β1 is highly expressed in the cerebral cor-
tex and hippocampus (19) compare to limited expression of 
PLC-β2 in hematopoietic cells (20, 21); PLC-β3 is found in the 
brain, liver, and parotid gland (22); PLC-β4 is present at the 
highest level in the cerebellum and retina (23-25). Our results 
showed that the highest EST score for PLC-β isozymes was 
found in the brain (~ 20-44% of analyzed EST sequences) 
(Table 1). EST sequences of PLC-β2 have greater value in blood 
and the bone marrow compare to other tissues. 
    Two mammalian subtypes of PLC-γ isozymes have been 
identified. PLC-γ1 mRNA is widely detected in various tissues. It 
is abundantly expressed in embryonal cortical structures, neu-
rons, oligodendrocytes and astrocytes (26) Unlike PLC-γ1, 
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Table 1. Tissue-specific expression of PLCs as deduced from human UniGene database
PLC-γ2 mRNA is expressed in the limited areas of anterior pitui-
tary and cerebellar Purkinje and granule cells (27). The ex-
pression of PLC-γ2 is primarily limited to cells of haemato-
poietic lineage. Our data search results revealed that the PLC-γ1 
EST number is high in the brain and embryonic tissues, while 
the highest PLC-γ2 EST number is observed in lymph nodes. 
The observed expression patterns can serve as an explanation to 
the predominant role of PLC-γ1 in embryonic cell development 
and the role of PLC-γ2 in immune response (28-30).
    PLC-δ1 is present in high abundancy in the brain, heart, 
lung, skeletal muscle and testis (31). EST sequences analysis 
showed that PLC-δ1 isozyme is found at high levels in the 
brain, lung, reproductive organs, thymus and connective tissue 
(Table 1). PLC-δ3 is detected abundantly in brain, skeletal 
muscle and heart (32). EST sequences for PLC-δ3 isozyme are 
mainly represented in brain, lung, pancreas, and reproductive 
organ (Table 1). PLC-δ4 mRNA is expressed in various tissues 
with the highest levels detected selectively in the brain, skel-
etal muscle, testis and kidney (33).
    PLC-ε mRNA expression has been detected in various tis-
sues, including brain, lung, and colon, with the highest ex-
pression detected in heart (34). Two splicing variants of PLC-ε 
have been reported, i.e., PLC-ε1a and PLC-ε1b. They have dif-
ferent sequences at the N-terminus that precedes the CDC25 
domain. PLC-ε1a transcripts are expressed in various tissues ex-
cept in peripheral blood leukocytes. PLC-ε1b mRNA has a lim-
ited expression in the placenta, lung and spleen. EST sequences 
of PLC-ε are dominant in connective tissues and brain.
    Northern blot analysis of mouse tissues and EST sequences 
analysis using human UniGene database showed that PLC-ζ is 
only found in the testis (35). However, PLC-ζ transcripts are 
detected in spermatid cDNA but not in testis cDNA in the ab-
sence of spermatid, suggesting that the PLC-ζ expression with-
in the testis is sperm-specific.
    Two PLC-η isozymes, PLC-η1 and PLC-η2, were identified 
in human and mouse. The highest level of PLC-η1 mRNA is 
observed in the brain and kidney and smaller levels are de-
tected in the lung, spleen, intestine, thymus and pancreas (36). 
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Fig. 2. Schematic diagram of alternative splicing variants for PLC isozymes in mouse. Schematic representing shows the PH domain, 
EF-hand motifs, catalytic X and Y domain, and C2 domain for the functional domains in all PLC isozymes. The total numbers of amino 
acid residues and GeneBank accession numbers for each splicing variant are written next to the diagram. The region of alternatively splic-
ing variants for PLC isozyme, which differ in their amoino acid residues, is indicated by a square with yellow and organge color. 
Insertion of addtional exon is indicated by red color. The position of alternatively splicing residue and insertion of additional residue at 
each PLC isozyme are labelled with arabic numerals in blue color. All of PLC-β transcripts are found to have two alternative splicing var-
iants, only differing in C-terminal sequences. Interestingly, in the mouse PLC-β2 gene, we found an alternative splicing variant form, con-
taining the truncated C-terminal region. Like alternative splicing variants of PLC-β, two different transcripts in C-terminal regions of PLC-γ1 
were identified in mouse. There are more than one additional transcripts found in PLC-δ isozyme in mouse. Surprisingly, mouse PLC-δ1b 
differs from PLC-δ1a by truncation of catalytic Y domain and C2 domain. Two and three alternative splicing variants of PLC-δ3 and -δ4 
exist in mouse, respectively. Mouse PLC-ε isozyme has two novel splicing variants at different region. Mouse PLC-ε1c lacks Ras-GEF do-
main and partial PH domain at N-terminus. In sperm-specific PLC-ζ, deduced amino acid sequences at C-terminal region differ from that 
of PLC-ζ in mouse. We found a novel splicing variant of mouse PLC-η1, excluding 20 amino acid residues in C-terminal region (we de-
signed it as PLC-η1d). In addition, we found the three different splicing variants of PLC-η2 in mouse. In PLC-γ isozymes, two SH2, SH3 
and split PH domain are indicated by green, pink and purple color, respectively. Protein GeneBank accession number of alternative splic-
ing variant for PLC is inserted in a bracket (*1: 28aa missing from methionine start site; *2: Nucleotide GeneBank accession number; *3: 
Exon1 and Exon2 missing; *4: 21aa missing from methionine start site).
PLC-η2 mRNA is detected in the brain and intestine (37, 38). 
Diverse splicing variants of PLCs
Most genes express a limited number of mRNA isoforms. But 
there are a number of genes that use alternative splicing to 
generate several numbers of isoforms. Alternative splicing var-
iants have been previously reported for several of PLC iso-
zymes including rat PLC-β1 (39), human PLC-β2 (40), rat 
PLC-β4 (41), rat PLC-δ4 (33), and human PLC-ε (42). Here, we 
analyzed and identified additional splicing variants for PLC 
isozyme using BLAST server in mouse species. Subsequently 
additional splicing variants for PLC isozyme were verified in 
exon-intron sequences from genomic sequences using UCSC 
Genome Bioinformatics web server (http://genome.ucsc.edu/ 
cgi-bin/hgBlat).
    Two splicing variants of the PLC-β1 isozyme derived from a 
single gene have been identified in human and rat that differ in 
their C-terminal sequences (39, 43). The mouse PLC-β1 gene 
possesses two alternative splicing variants. PLC-β1a contains 
putative NLS (nuclear localization sequences) and NES (nuclear 
export sequences) regions. Two variants of PLC-β isozyme dif-
fer in their cellular localization, suggesting that this region reg-
ulates the transit in and out of the nucleus (39). Two splicing 
variants of human PLC-β2 were reported; PLC-β2a and 
PLC-β2b. They differ in 15 amino acid residues at the C-termi-
nal region as was shown in haematopoietic cells (21, 40). In 
the case of mouse PLC-β2 gene, we have found a splicing var-
iant, which has truncated the entire C-terminal region. The al-
ternative splicing variant of the mouse PLC-β3 gene showed 
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that it contains the internal stop codon between 3039 and 
3040 open reading frame in the wild PLC-β3 gene. Several al-
terative splicing variants of PLC-β4 have been reported. We 
found and identified two alternative splicing variants from rat 
and bovine brain (24, 41, 44). The third splicing variant of rat 
PLC-β4 has an additional 37 nucleotide exon at the C-terminal 
region (23). All PLC-β genes have two alternative splicing var-
iants, which differ in their C-terminal sequences (Fig. 2).
    Two alternative splicing variants of PLC-γ1 were found to dif-
fer in their C-terminal sequences. The distinct function of the 
two alternative splicing variants still remains unknown. Only 
one transcript of the PLC-γ2 gene was identified in the mouse 
(Fig. 2). 
    Alternative splicing variants of PLC-δ isozymes represent 
several different patterns of splicing variants unlike those of 
PLC-β isozymes. Mouse PLC-δ1b differs from PLC-δ1a by 274 
amino acid residues that extend from the catalytic Y domain to 
the stop sequence, which are replaced with 21 distinct amino 
acid residues. Mouse PLC-δ1b has a truncated catalytic Y do-
main, which implies that this variant may have no enzymatic 
activity. PRIP-1 (PLC-related inactive protein-1) has a high se-
quence similarity to PLC-δ1 but has no PIP2-hydrolyzing 
activity. PRIP-1 regulates IP3-mediated Ca2＋ signaling by bind-
ing of IP3 (45). It would be interesting to investigate whether 
PLC-δ1b can also have such a regulatory function in PLC 
signaling. The second splicing variant of PLC-δ3 demonstrates 
the deletion of 51 nucleotides between the PH domain and 
EF-hand motifs. There are three alternative splicing variants of 
mouse PLC-δ4 (Fig. 2). PLC-δ4a contains additional 32 amino 
acid residues in the linker region between the catalytic X and Y 
domains. The earlier study reported that all of the above three 
splice variants have the catalytic X domain and/or the linker re-
gion for X and Y domains (46). We found an additional splicing 
variant of PLC-δ4b that is different from the earlier reported 
PLC-δ4 isoforms at the C-terminal region.
    Two splicing variants of human PLC-ε with a different N-ter-
minal region have been reported (42), but mouse PLC-ε iso-
zyme was found to have two novel splicing variants in a differ-
ent region. Surprisingly, mouse PLC-ε1c lacks the Ras-GEF do-
main and partial PH domain at the N-terminus. Additionally, 
we searched the mouse EST database and identified one EST 
clone (EST clone; CJ197436) that included partial sequences 
for N-terminus of PLC-ε1c.
    s-PLC-ζ, an alternative splicing variant for PLC-ζ has been 
reported (47). It contains two internal stop codons at the N-ter-
minus and lacks one and a half of EF-hand motifs. It was re-
ported that this splicing variant of PLC-ζ does not affect Ca2＋ 
oscillations. Moreover, we found an additional splicing variant 
of PLC-ζ, which has the C-terminal sequence different from 
that of s-PLC-ζ. 
    Three splicing variants of PLC-η1 have been reported in hu-
man and mouse (36). We found a novel splicing variant of 
mouse PLC-η1. It excludes 20 amino acid residues in the C-ter-
minal region (designated as PLC-η1d; Fig. 2). Five alternative 
splicing variants of PLC-η2 exist in human (37), and three splic-
ing variants of PLC-η2 have been found in mouse. PLC-η2b 
and PLC-η2c contain additional 74 amino acid residues at 
N-terminal region. Moreover, splicing variant of PLC-η2c differ 
from the other PLC-η2 subtypes at the C-terminal region.
Molecular function and regulation of PLCs
PLC-β isozymes
Regulation of PLC-β subtype activity: PLC-β is a member of a 
large family of PLC enzymes and includes PLC-β1~4. PLC-β 
isozymes share many of the structural features present in other 
members of the PLC family, including conserved catalytic X 
and Y domains as well as two membrane-phospholipid bind-
ing regions, the PH and C2 domains. PLC-β isozymes, how-
ever, are distinguished by the presence of an elongated C-ter-
minus consisting of about ~450 residues, which contains 
many of the determinants for interaction with Gq as well as for 
other functions such as membrane binding and nuclear local-
ization (3, 48-50). 
    Four PLC-β isotypes and additional splicing variants have 
been identified in mammals. These isoforms are regulated by 
heterotrimeric GTP-binding proteins, and have a high GTPase 
stimulating (GAP) activity. Mammalian PLC-β isozymes are dif-
ferentially distributed in tissues, with the PLC-β1 being most 
widely expressed, especially in specific regions of the brain. 
PLC-β1 exists as alternative splicing variants PLC-β1a and 
-β1b, which differ in their C-terminal residues (39). The pri-
mary transcript of PLC-β4 gene is also alternatively spliced in 
the region corresponding to the C-terminal region of the pro-
tein downstream of the C2 domain (41). In the cytoplasm, 
PLC-β functions as effector enzymes for receptors belonging to 
the rhodopsin superfamily of transmembrane proteins that con-
tain seven transmembrane spanning segments. They are acti-
vated by a variety of stimuli and require special combinations 
of Gα and Gβ /γ subunits to couple to the effector (3). 
Activation could be also induced by phosphatidic acid (PA) in 
that recent studies suggest a novel role for PA in the regulation 
of GPCR signal transduction that is mediated through PLC β1 
homodimerization (51). With the exception of PLC-β4, PLC-β 
isozymes are also activated by Gβγ dimmers (52-55). The rela-
tive sensitivity of PLC-β isozymes to Gβγ subunits differs from 
that to Gqα subunits; PLC-β1 is the least sensitive to Gβγ (52, 
53). Direct binding measurements indicate that, although the 
Gβγ dimer interacts with PLC-β1, -β2, and -β3, it exhibits a 
high affinity only for PLC-β2 (56).
    It has been shown that a variety of physiological stimuli that 
activate PLC-β isozymes in normal platelets were not able to 
activate these isozymes in platelets derived from αq knockout 
mice; αq is the only member of the Gqα subfamily expressed 
in normal platelets (57). Thus, Gαq appears essential for PLC-β 
activation and cannot be replaced by Gβγ in this regard. The 
region of PLC β that interacts with Gqα subunits differs from 
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that responsible for interaction with Gβγ. Thus, C-terminal 
truncation of PLC-β2 generated enzymes that were activated 
by Gβγ but not by Gαq (58). The PH domain of PLC-β2 exhibits 
high affinity for Gβγ subunits bound to membranes (59). Experi-
ments with antisense oligonucleotides directed to mRNAs en-
coding various G protein subunits suggested that the m1 mus-
carinic acetylcholine receptor interacts only with G protein 
complexes composed of the subunits αq, α11, β1, β4, and γ 4 
in order to activate PLC in RBL-2H3 cells, despite the fact that 
the subunits α14, β2, β3, γ2, γ3, γ5, and γ7 are also expressed 
in these cells (60). G protein–initiated signaling is turned off by 
hydrolysis of the GTP bound to the Gα subunit, a reaction cat-
alyzed by the intrinsic GTPase activity of the α subunit itself, 
and the subsequent reassociation of the GDP-bound α subunit 
with the βγ subunits. This deactivation process was studied in 
detail by reconstituting the m1 muscarinic acetylcholine re-
ceptor, G protein, and PLC-β1 in lipid vesicles (61).
PLC-β1 isozyme present the nucleus is located in nuclear 
speckles: PLC signaling occurs not only at the plasma mem-
brane but also in the nucleus (62, 63). PLC-β1 is the major 
PLC isozyme in the nucleus of various cells (64, 65), and the 
C-terminal region of the protein is required for nuclear local-
ization, even though also PLC-β2, -β3 and -β4 have been 
shown to be in this organelle (66). 
    Where is located PLC-β1 located in the nucleus? PLC-β1 has 
been reported to localize to nuclear speckles, together with PIP 
kinases, PIP2, diacylglycerol kinase θ (DGK θ), PLC-δ4, PI 
3-Kinase C2α, phosphatase and tension homologue deleted on 
chromosome 10 (PTEN) and SH2-domain containing inositol 
phosphatase 2 (SHIP2) (67-69). It has been demonstrated an as-
sociation between PLC-β1 and both DGK ζ and PIP Kinase α, in 
immunoprecipitation experiments with a PLC-β1 specific 
antibody. With immuno-electron microscopy we also showed 
that DGK θ, PLC-β1 and PIP2 are associated to electron-dense 
particles within the nucleus, that correspond to nuclear speck-
les as revealed by using the antibody against SC-35 (70).
PLC-β1 in hematological malignancies: The involvement of 
PLC-β1 in hematopoietic differentiation, i.e. affecting CD24 
expression (71) prompted us to investigate the role of this sig-
naling molecule in hematological malignancies, focusing par-
ticularly on patients affected by myelodysplastic syndromes 
(MDS) at higher risk of evolution into acute myeloid leukemia 
(AML). By using fluorescence in situ hybridization (FISH) anal-
ysis, our group demonstrated, in a small number of high-risk 
MDS patients (72), that subjects bearing a mono-allelic cryptic 
deletion of the PLC-β1 gene had a worse clinical outcome, as 
compared with patients having both alleles. In a subsequent 
study, it has also been shown that the expression profile of 
both PLC-β1a and PLC-β1b mRNAs, which are the two alter-
native splicing subtype of PLC-β1, is altered in high-risk MDS, 
as compared to healthy donors. Interestingly, MDS cells al-
ways expressed higher levels of PLC-β1b mRNA as compared 
to PLC-β1a mRNA; this difference may reflect a specific role of 
PLC-β1 in MDS, given that the PLC-β1a splicing subtype dem-
onstrates both nuclear and cytoplasmatic localization, while 
PLC-β1b splicing subtype is localized only in the nucleus. 
Furthermore, our recent studies demonstrated that not only is 
Akt specifically phosphorylated in high-risk MDS patients, but 
also mTOR and its downstream targets are activated (73), af-
fecting cell survival and proliferation of MDS cells. 
PLC-β isozyme expression and the epigenetic effect of DNA 
methyltransferase inhibition: Interestingly, it has been shown 
that a DNA methyltransferase inhibitor currently approved for 
the treatment of MDS and under experimental evaluation for 
other hematological malignancies, i.e. azacitidine, also affects 
PLC-β1 expression (74). Besides showing response rates of 
50–80% in MDS, azacitidine has been reported to have a sig-
nificant impact on the quality of life and progression into AML 
(75). Nevertheless, the molecular mechanisms underlying this 
drug are not completely understood. Low-dose regimens with 
azacitidine have been assumed to act by reversing the epi-
genetic silencing of target genes involved in the control of cell 
growth and differentiation. However, although demethylation 
of a hypermethylated p15/ INK4B gene has been demonstrated 
in MDS patients treated with demethylating therapy (76), this 
observation does not necessarily mean that this is the main 
mechanism of action of the drug in vivo. Moreover, since p15 
is unlikely to be the only hypermethylated and silenced gene 
in MDS, it was important to examine the presence of other tar-
gets for demethylating treatment. We have shown that in pa-
tients diagnosed with MDS who was treated with azacitidine a 
correlation of PLC-β1 expression with an almost complete re-
mission (77). In particular a patient after reaching a partial 
hematologic remission, following the International Working 
Group (IWG) response criteria (78) and temporarily decreased 
hematological response, subsequently restored, finally reached 
a complete remission. During the therapy, the patient demon-
strated an increase in PLC-β1 expression, as well as a down-
regulation in the level of activated Akt, postulating an associa-
tion between PLC β1 expression and azacitidine effectiveness. 
All in all these observations hint at the likelihood that nuclear 
PLC-β1 is a good candidate for both MDS prognosis and epi-
genetic effect of antileukemic drugs. Indeed the fact that 
PLC-β1 could at the nucleus in a peculiar way, different from 
that at the plasma membrane, i.e. as a check point for the G1 
phase of the cell cycle, is strengthened by the results showing 
that nuclear PLC-β1 activity is switched on and off by phos-
phorylative events and targets cyclin D3 during both cell 
growth and differentiation (79-81).
Functions of PLC-β isozyme in mice: PLC-β1 null mice showed 
the epileptic seizures and this led to the sudden death of the 
mice. This result suggests that PLC-β1 is essential for the normal 
functioning of inhibitory neuronal circuitry (82). Chemoattrac-
tant-mediated PLC activity was impaired in the neutrophills iso-
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lated from PLC-β2-deficient mice. This led to the decreased in-
tracellular calcium release, superoxide production and cell sur-
face expression of MAC-1 (83). PLC-β3-null mice demonstrated 
increased sensitivity to morphine compared with the wild type 
mice, which indicates that PLC-β3 is a significant negative mod-
ulator for opioid response (84). The mice lacking PLC-β4 showed 
the ataxia and impaired visual processing, which are results of 
impaired PLC-linked signal transduction (82, 85).
PLC-γ isozymes
Regulation of PLC-γ isozyme activity: Two mammalian PLCγ 
forms (PLC-γ1 and PLC-γ2) have been identified. As described 
in previous sections, these enzymes are characterised by the in-
sertion of a highly structured region (PLC-γ-specific array, γSA) 
comprising a split PH domain flanking two tandem SH2 do-
mains and SH3 domain between the two halves of the TIM-bar-
rel catalytic domain (86, 87). This region has been implicated 
in activation of PLC-γ isozymes downstream of receptors with 
intrinsic or associated tyrosine kinase activity. Although not 
fully understood, regulatory mechanisms are best characterised 
for PLC-γ1 activated in response to polypeptide growth factors 
that bind to receptor tyrosine kinases (RTKs) such as the epi-
dermal growth factor receptor (EGFR) and platelet-derived 
growth factor receptor (PDGFR) (88, 89). The SH2 domains of 
PLC-γ1 mediate binding to autophosphorylated tyrosine resi-
dues within the intracellular region of the receptor; this associa-
tion is important for both membrane recruitment and tyrosine 
phosphorylation of PLC-γ1. Growth factor stimulation, such as 
stimulation by PDGF, induces PLC-γ1 phosphorylation at three 
tyrosine residues: Tyr771 and Tyr783 within the γ-specific region 
and Tyr1254 within the C-terminal tail; however, a recent study 
has shown that only phosphorylation at Tyr783 is essential for li-
pase activation (90). This has been attributed to the intra-mo-
lecular binding of phosphorylated Tyr783 to the C-terminal SH2 
domain and further speculated that this interaction induces a 
conformational change required for activation (91).
    PLC-γ1 and PLC-γ2 can also be activated downstream of a va-
riety of receptors that lack intrinsic tyrosine kinase activity. For 
PLC-γ1 this has been reported for receptors including GPCRs 
such as the angiotensin II and bradykinin receptors, cytokine re-
ceptors and immunoreceptors such as the T cell receptor (92-95). 
PLC-γ2 is activated downstream of immunoglobulin and adhe-
sion receptors on immune cells such as B cells, platelets and 
mast cells (96-98). In these instances, PLC-γ isozymes are phos-
phorylated by non-receptor tyrosine kinases in the context of 
membrane-localised multimolecular signalling complexes. These 
assemblies have been well characterised in the context of anti-
gen receptor signalling on B and T cells and include kinases of 
the Src, Syk and Tec families in addition to adaptor molecules 
such as BLNK and LAT that serve to recruit the different compo-
nents to the complex (99). In tumour cells and some non-neo-
plastic cells, PLC-γ1 interacts with another important adaptor 
protein GIT1 (GPCR kinase-interacting protein-1) (100-102). 
This interaction facilitates Src kinase-mediated PLCγ1 activation 
downstream of GPCRs, RTKs and integrins and thereby could 
integrate signal transduction inputs emanating from these differ-
ent classes of receptor (100-102).
    The multi-domain structure of PLC-γ1 permits interactions 
with a whole host of additional binding partners. The SH2 do-
mains, SH3 domain and split PH domain have all been im-
plicated in various protein/protein interactions. Some of these 
interactions, including EF-1α and the inositol 5’-phosphatase, 
SHIP1, enhance PLC-γ1’s activity whereas others such as Cbl 
and Grb2 serve as negative regulators of the enzyme (103-106). 
Localization and activation of PLC-γ isozymes at the cell pe-
riphery are also governed by direct interactions with F-actin 
and are therefore subject to changes in the architecture and 
functioning of the cytoskeleton (107-110).
Function of PLC-γ  isozyme in mice: The expression patterns of 
PLC-γ1 and PLC-γ2 show some degree of overlap; however, 
even in regions of co-expression, the two isoforms appear to 
perform independent, non-redundant functions (111). PLC-γ2 is 
most highly expressed in cells of the haematopoietic system 
and plays a key role in regulation of the immune response (19, 
112). Consistent with this, PLC-γ2 null mice display defects in 
the functioning of B cells, platelets, mast cells and natural killer 
cells (29, 30). Loss of PLC-γ2 signalling in human B cells under-
lies the immunodeficiency syndrome X-linked agammaglobuli-
naemia (113). Furthermore, a point mutation in the murine 
PLC-γ2 gene has been linked to inflammatory and autoimmune 
responses through PLC-γ2 hyperactivation in cells of both the 
innate and acquired immune system (114).
    PLC-γ1, in contrast, is ubiquitously expressed and appears to 
regulate a multitude of cellular functions in many tissues. PLC-γ1 
null mice die by embryonic day 9 highlighting the widespread 
importance of this enzyme (115). Although PLC-γ1 is classically 
activated in response to growth factor stimulation, its role in the 
regulation of cell proliferation remains controversial. Neutrali-
sing antibodies and dominant negative PLC-γ1 fragments have 
been used to demonstrate a role for PLC-γ1 in mitogenic signal-
ling (116, 117). However, observations made using signalling- 
restricted receptors and PLC-γ1 null fibroblasts support the idea 
that PLC-γ1 is not required for growth factor-stimulated pro-
liferation (28, 116-118). More definitive roles for PLC-γ1 have 
been established in the regulation of cellular differentiation and 
survival programmes (119-121). Recently, several studies im-
plicated PLC-γ1 as a determinant of the directionality of cell 
movement towards EGF and proposed that it can couple to the 
actin polymerisation machinery via multiple routes including 
regulation of coffilin and Rac/Cdc42 GTPases (122). Further-
more, in vivo data where PLCγ activity is compromised support 
on important role for PLC-γ1 in cancer metastasis (123, 124).
Brain function in PLC-γ  isozyme: PLC-γ1 also contributes to the 
functioning of specific cell types. Within the immune system, 
PLC-γ1 regulates the activation of T cells and mast cells there-
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by complementing the role played by PLC-γ2 (125-127). In the 
brain, PLC-γ1 is activated in response to Nyk, fibroblast growth 
factor (FGF), and Trk family RTKs and has been implicated in 
the regulation of neuronal differentiation and neurite out-
growth (128, 129). There is also evidence to suggest that 
PLC-γ1 forms an integral part of neural networks that underlie 
disparate features of brain function such as emotion, memory 
and motor activity (130-132). Consistent with the involvement 
of PLC-γ1 in the regulation of mood, polymorphisms in the hu-
man PLC-γ1 gene have been linked to the pathogenesis of bi-
polar disorder (133).
    Some of the roles of PLC-γ1 in the brain may be linked to 
regulation of ion channel function, as many ion channels are 
acutely sensitive to the levels of membrane PIP2 (134). 
PLC-mediated hydrolysis of PIP2 underlies the rapid sup-
pression of multiple potassium channel currents (135-137). 
PLC-γ1 has also been shown to regulate agonist-induced cal-
cium entry through plasma membrane channels of the canon-
ical TRP (transient receptor potential) family (138, 139); this ef-
fect is independent of PLC-γ1-mediated calcium release from 
intracellular stores. The second messenger DAG can directly 
activate several TRPC channels (140, 141); however, studies 
have shown that this function is independent of PLC-γ1’s li-
pase activity and relies on the direct binding of PLC-γ enzymes 
and TRPC3 (139). A model has been proposed whereby the 
C-terminal half of PLC-γ1’s split PH domain associates with a 
region on TRPC3 to form a lipid-binding intermolecular PH 
domain although subsequent structural data suggest that the 
split PH domain of PLC-γ1 folds together to form an intact in-
ternal PH domain (16, 142).
PLC-γ  isozyme is involved in cellular proliferation: Several ad-
ditional studies have reported on phospholipase-independent 
functions of PLC-γ1. Early studies focusing on the role of 
PLC-γ1 in proliferation demonstrated that lipase activity was 
dispensable for induction of DNA synthesis in quiescent fibro-
blasts and attributed the mitogenic properties of the catalytic 
mutant to the SH3 domain (143, 144). Binding sites for many 
PLC-γ1 interaction partners have been mapped to the SH3 do-
main (145, 146); in particular, SH3 domain binding of the Ras 
exchange factor, SOS1, enhances Ras activation providing a 
potential link to cell cycle regulation (147). More recently, it 
has been reported that the SH3 domain of PLC-γ1 can act as a 
guanine nucleotide exchange factor (GEF) for the brain-specific 
nuclear GTPase PIKE (PI3K enhancer) and dynamin-1 (148, 
149). This novel activity of PLCγ1 may underlie several fea-
tures of PLC-γ1 cellular function including regulation of pro-
liferation and survival (150, 151). 
    One aspect of study of PLC-γ isozymes recently consolidated 
and further extended their regulatory and biological roles. In 
addition to growth factors and immune receptors, integrins 
have been shown to activate PLC-γ isozymes in specific cell 
types including osteoclasts, fibroblasts and T cells (152-155). 
Further, PLC-γ2 activation downstream of integrins in platelets 
has been implicated in the regulation of platelet adhesion and 
spreading (156-158) and several studies show that PLC-γ1 may 
also regulate cell attachment and morphology (152, 155). In 
keeping with the involvement of PLC-γ isozymes in influencing 
the dynamics of cell shape, PLC-γ1 plays a role in the regu-
lation of cell migration not only in response to growth factors 
but also downstream of integrin engagement, as observed in 
several cell types including tumour cells, endothelial cells and 
fibroblasts (101, 159). 
PLC-δ isozymes
Regulation of PLC-δ isozyme activity: PLC-δ is considered the 
most basic isozyme because its structure is very simple, com-
prising a PH domain, EF hand motif, X and Y domains, and C2 
domain. In addition, comparison of DNA sequences suggests 
an evolutionary relation in which PLC-δ appeared in primitive 
eukaryotes. PLC-δ isozyme is composed of three isozyme, 
PLC-δ1, -δ3, and -δ4 (160), and similarities in amino acid of 
each domain between these isozymes are very high. 
    PLC is a basically soluble protein that is localized mainly in 
the cytosol, and it is translocated to the plasma membrane, 
where it functions to hydrolyze PIP2, in response to cell acti-
vation. Thus, targeting of PLC to the plasma membrane is a crit-
ical event for generating signals. Lemmon et al. proposed the 
“tether and fix” theory, by which binding to plasma membrane 
and activation of PLC-δ1 were described (161). First, PLC-δ1 is 
tethered to the plasma membrane through interactions of PH 
domain and PIP2. This is still inactive form. Additional other ac-
tions with the membrane mediated by the C2 domain and cata-
lytic domains expose the active site. This fixed (active) form hy-
drolyzes PIP2 efficiently. This process may be triggered by a 
small increase in intracellular calcium concentration ([Ca2＋]i). 
Although all PLC isozymes require calcium for activity, 
PLCδ-isozyme  is one of the most sensitive to calcium, suggest-
ing activity of PLCδ-isozyme  is regulated by [Ca2＋]i (162, 163). 
It is also worth noting that Gα (h). (tissue transglutaminase II 
(TGII)) associates directly and activates PLC-δ1 in vitro (164). 
TGII has transglutaminase activity as well as GTPase activity. 
More recent report indicated that expression of TGII mutants 
lacking the interaction with α-adrenoreceptor (αAR) or PLC-δ1 
reduced the increase in [Ca2＋]i (165), suggesting the involve-
ment of PLC-δ1 in αAR signaling. Very interestingly, Rho 
GTPase-activating protein (RhoGAP), p122, was also reported 
to bind and activate PLC-δ 1 directly (166). Microinjection of 
the GTPase-activating domain of p122 suppressed the for-
mation of stress fibers and focal adhesions induced by lysophos-
phatidic acid, suggesting a specific GTPase-activating activity of 
p122 for Rho (167). These results demonstrate that p122 synerg-
istically functions as a RhoGAP and an activator of PLC-δ1 in 
vivo and induces cytoskeletal reorganization.
Functions of PLC-δ isozyme in mice: Loss of function in PLC-δ 
isotype gene-deficient mice has revealed the critical function 
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of each PLC isozyme in vivo. PLC-δ1 null mice showed marked 
hair loss associated with abnormal hair follicle structures and 
epidermal hyperplasia in interfollicle epidermis (168). Hyper- 
thickened epidermis and increased dermal cellularity are often 
observed in mice with skin inflammation (169). In fact, ex-
pression of IL-1β and IL-6, pro-inflammatory cytokines, was in-
creased significantly and infiltration of leukocytes such as mac-
rophages, granulocytes, and T lymphocytes was observed in 
skin of PLC-δ1 null mice (170). These findings suggest that lack 
of PLC-δ1 results in induction of skin inflammation. Since these 
defects were clearly canceled by treatment of PLC-δ1 null mice 
with potent anti-inflammatory reagents, epidermal hyperplasia 
of PLC-δ1 null mice may be caused by skin inflammation. 
    The appearance of a PLC-δ1 null mouse is very similar to 
that of a nude mouse (171). Hematoxylin and eosin (HE)-staining 
of skin sections from PLC-δ1 null and nude mice revealed that 
the hair shafts of both mice are bent and fail to penetrate the 
epidermis. In nude mice, the gene encoding the transcription 
factor Foxn1 is spontaneously mutated (172), and this mutation 
leads to insufficient hair keratin mHa3 expression and abnor-
mal hair shaft structures (173). Expression of mHa3 was de-
creased remarkably in the skin of PLC-δ1 null mice. In addition, 
exogenously expressed Foxn1 induced the expression of PLC-δ1, 
indicating that Foxn1 functions as an upstream molecule of 
PLC-δ1. Furthermore, in situ hybridization analysis revealed 
that PLC-δ1was abundantly expressed in hair follicles of control 
mice, whereas only faint expression of PLC-δ1 was observed in 
hair follicles of nude mice. These results indicate that Foxn1is 
the upstream regulator of PLC-δ1 expression and that PLC-δ1 
may be involved in the pathway from Foxn1 to hair keratin 
mHa3 expression.
    Although PLC-δ3 null mice show no abnormality so far, 
PLC-δ1/-δ3 double null mice resulted in embryonic lethality at 
E11.5-E13.5 caused by differential defect of placental develop-
ment (174). PLC-δ1/-δ3 double null mice exhibited severe dis-
ruption of the normal labyrinth architecture in the placenta. 
The labyrinth layer of placenta contains a large number of ma-
ternal and embryonic vessels and is the exchange site of oxy-
gen, nutrient, and waste between mother and embryo. 
Remarkably, the numbers of these vessels in the labyrinth layer 
of PLC-δ1/-δ3 double null mice placentas were severely 
reduced. Furthermore, PLC-δ1/-δ3 double null mice embryos 
supplied with a normal placenta by the tetraploid aggregation 
method (175) survived beyond E14.5 and the placenta of res-
cued PLC-δ1/-δ3 double null mice embryos contained many 
maternal and embryonic vessels, clearly showing that the em-
bryonic lethality is caused by a defect in trophoblasts. These 
results indicate that PLC-δ1 and PLC-δ3 are essential in tropho-
blast for placental development. 
    PLC-δ4 null mice appeared healthy, however, PLC-δ4 null 
male mice either produced a few smaller litters or are sterile 
(176). In vitro fertilization studies showed that insemination 
with PLC-δ4 null mice sperm resulted in significantly fewer 
eggs becoming activated and that the calcium transients asso-
ciated with fertilization are absent or delayed. These results 
suggest that PLC-δ4 in sperm plays an essential role in an early 
step of fertilization. Histochemical analysis of testes revealed 
that PLC-δ4 is concentrated in the anterior acrosomal region of 
sperm. Furthermore, PLC-δ4 null mice sperm were unable to 
initiate the acrosome reaction, an exocytotic event required for 
fertilization and induced by interaction with the egg coat, the 
zona pellucida (ZP). These data demonstrate that PLC-δ4 func-
tions in the ZP-induced acrosome reaction during mammalian 
fertilization. [Ca2＋]i has a primary role in the execution of the 
acrosome reaction (177, 178). Wild-type sperm treated with 
ZP exhibited a continuous [Ca2＋]i increase. In contrast, the ad-
dition of ZP induced a minor [Ca2＋]i increase in PLC-δ4 null 
mice sperm (179). These data indicate that the abnormal acro-
some reaction induced by ZP in PLC-δ4 null mice’s sperm is 
due to impaired intracellular [Ca2＋]i mobilization in these 
sperm and that PLC-δ4 plays a crucial role in the acrosome re-
action during natural fertilization.
PLC-δ1 is identified as anti-oncogene: Recently PLC-δ1 was 
identified as anti-oncogene protein in human. Since chromo-
some 3p22 was frequently deleted in esophageal squamous 
cell carcinoma (ESCC), Fu et al. searched genes that is located 
in this region and found that PLC-δ1 is a strong candidate for tu-
mor-suppressor gene (180). Absent expression of PLC-δ1 was 
frequently detected in both primary ESCCs and ESCC cell lines, 
which was significantly associated with the promoter 
hypermethylation. They also reported introduction of PLC-δ1 
into ESCC cells suppressed their tumorigenic ability assayed by 
colony formation in soft agar and tumor formation in nude 
mice. In addition, down-regulation of PLC-δ1 protein was sig-
nificantly correlated with ESCC metastasis. Taken together with 
the observations of hyperprasia and enhanced proliferation in 
the skin of PLC-δ1 null mice, PLC-δ1 may play an important 
suppressive role in the development and progression of ESCC.
    On the other hand, Yuan et al. isolated a new gene fre-
quently deleted in liver cancer, DLC-1. Human DLC-1 shares 
high homology with rat p122 RhoGAP (181), a PLC-δ1-binding 
protein as described before. Since DLC-1 inhibited human 
cancer cell growth and the in vivo tumorigenicity in nude 
mice, it may possible that p122 functions as an anti-oncogene 
by synergic interaction of PLC-δ1 and bying modulating the 
Rho-mediated actin cytoskeleton.
Nuclear function of PLC-δ1: Yagisawa’s group first reported 
that PLC-δ1 has both nuclear export and import sequences that 
contribute to its shuttling between the cytoplasm and nucleus 
(182). Although PLC-δ1 is generally found in the cytoplasm of 
quiescent cells, it localizes in nuclear structures in the G1/S 
boundary of the cell cycle (183). Recently Rebecchi’s group 
demonstrated that suppression of PLC-δ1 by siRNA increases 
the level of cyclin E, a key regulator of the G1/S boundary, al-
ters S-phase progression, and inhibits cell proliferation (184). In 
addition, transient expression of PLC-δ1 suppressed the ex-
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pression of cyclin E at the G1/S boundary. These results suggest 
that PLC-δ1 plays a role in cell cycle. Taken together with the 
report that nuclear PIP2 level was increased to several folds at 
the G1/S boundary and at least doubled at G0, respectively, the 
change in the PIP2 level may regulate nuclear functions such as a 
chromatin remodeling mediated by mammalian SWI/SNF-like 
BAF complex (185).
PLC-δ1 is involved in osmotic response: To understand trans-
ductions of mechanical and osmotic stimuli, Ferrer-Montiel’s 
group used an expression cloning approach to screen a human 
dorsal root ganglion cDNA library to look for proteins that re-
spond to hypotonicity by raising the [Ca2＋]i (186). They identi-
fied GAP43, a membrane-anchored neuronal protein impli-
cated in axonal growth and synaptic plasticity, as an osmo-
sensory protein that induces [Ca2＋]i in response to hypotonicity. 
Interestingly, hypotonicity promoted the selective association of 
GAP43 with PLC-δ1, and concomitant increase in IP3 formation. 
These findings indicate that PLC-δ1 is involved in the pathway 
from hypo-osmotic activation of GAP43 to Ca2＋ increase. 
Specific extracellular stimuli or receptors that couple to PLC-δ1 
have not been well clarified yet, though, these results suggest 
that the most primitive and evolutionary conserved type of 
PLC-δ plays a role in the most fundamental situation.
PLC-ε isozyme
Regulation of GPCR-mediated PLC-ε activity: PLC-ε was first 
identified in C. elegans as a novel effector molecule of LET-60, 
nematode Ras (187). Three independent research groups have 
identified the mammalian PLC-ε in 2001 (34, 188, 189). It is 
the largest PLC isozyme identified up to date that has two do-
mains which are not found in other PLC isozymes. RA do-
mains are located at the C-terminus of PLC-ε and mediates 
GTP-dependent interaction with Ras family small G-proteins 
such as Ras or Rap (189, 190). CDC25 homology domain is lo-
cated at the N-terminus of PLC-ε and functions as a guanine 
nucleotide exchange factor (GFF) for Rap1A, one of Ras family 
small G-proteins (191). These structural features suggest that 
PLC-ε has a role in interplay between the Ras-mediated and 
PLC- dependent signaling pathways.
    Various ligands can lead to activation of PLC-ε. Several li-
gands of Gαs-coupled GPCRs such as adrenaline and PGE1 acti-
vate PLC-ε (192, 193). Epac, a cyclic adenosine-3’5-mono-
phosphate (cAMP)-dependent GEF for Rap GTPases, activates 
Rap2B upon GPCR stimulation. Activated Rap2B then associates 
with the RA2 domain of PLC-ε and induces PIP2 hydrolysis. 
GPCR ligands coupled with Gα12 and Gα13 such as LPA, S1P 
and thrombin, can activate PLC-ε (194-196). Various RhoGEFs 
are activated by Gα12 and Gα13 and they induce the formation 
of GTP-loaded RhoA. Activated RhoA stimulates PLC-ε activity 
by direct binding to the specific region of the PLC-ε Y domain. 
Several GPCR ligands such as LPA, thrombin and endothelin 
can activate PLC-ε as well as PLC-β. The isozyme-specific function 
of PLC-β or PLC-ε in GPCR signaling remains to be revealed. 
However, Kelly et al. suggested that activation of these isoforms 
occurs in a temporally distinct manner whereby PLC-β3 is acti-
vated acutely and PLC-ε in a sustained manner (195). 
Regulation of growth factor-mediated PLC-ε activity: PLC-ε is 
activated by stimulation with growth factors such as EGF and 
PDGF. Upon growth factor stimulation, activated Ras recruits 
PLC-ε into the plasma membrane through direct association 
with the RA2 domain (189). PLC-ε also translocates to the peri-
nuclear area to associate with activated Rap1A. The CDC25 
domain of PLC-ε functions as a GEF for Rap1A and helps persis-
tent Rap1A-dependent PLC-ε activation (191). RA2 domain also 
mediates the interaction with ubiquitin E3 ligase Siah, which 
leads to growth factor-dependent degradation of PLC-ε (197).
    The relationship between PLC-γ1 and PLC-ε in growth fac-
tor-dependent signaling remains to be revealed. Kataoka et al 
demonstrated that a PDGF receptor mutant deficient in PLC-γ1 
docking site retains its ability to activate PLC-ε (198). However, 
Schmidt et al. suggested that PLC-γ1 can be an upstream regu-
lator of PLC-ε and may exert the effect via activation of RasGRP3 
and Rap2B (199).
Function of PLC-ε isozyme in mice: Null mice studies revealed 
that PLC-ε plays a role in heart development and functions. 
Kataoka et al. showed that the ablation of PLC-ε leads to the 
defects in the development of the aortic and pulmonary valves 
(200). On the other hand, Smrcka et al. reported that mice 
lacking PLC-ε showed decreased contractile responses to acute 
isoproterenol administration, which indicates that the loss of 
PLC-ε can sensitize the heart to the development of hyper-
trophy in response to chronic cardiac stress (201). PLC-ε is also 
important for the development of several other organs. Hinkes 
et al. reported that mutations in the catalytic region of PLC-ε 
resulted in the human renal pathology such as diffuse me-
sangial sclerosis or focal semental glomerulosclerosis (202). It 
is suggested that the absence of PLC-ε may block kidney devel-
opment at the capillary loop stage leading to the renal failure. 
Epidermal morphogenesis of C. elegans requires PLC-ε and its 
knock-down or mutation caused embryonic lethality (203).
PLC-ε is involved in cell proliferation: Several reports showed 
that PLC-ε is involved in cell proliferation. Mice lacking PLC-ε 
activity are less susceptible to carcinogen induced tumor for-
mation (204). It was suggested that PLC-ε-dependent potentia-
tion of skin inflammation is responsible for the promoting tu-
mor formation (205). In addition, it was evidenced that PLC-ε 
plays a role in agonist-dependent proliferation. PLC-ε induced 
PDGF-dependent cell growth in BaF3 cells overexpressing 
PDGF receptor (198) or EGF-dependent cell growth in HEK293 
cells or MEF cells (197, 206). A recent report indicates that 
thrombin-dependent astrocyte proliferation is mediated by 
PLC-ε (207). In that report, GEF activity of PLC-ε was required 
for the Erk activation and cell astrocyte proliferation. In addi-
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tion, PLC-ε promotes EGF-dependent cell growth by inhibition 
of EGF receptor downregulation (206). Taken together, PLC-ε 
seems to promote cell growth contributing to the normal devel-
opmental processes or tumor formation. 
PLC-ζ and PLC-η isozymes
Regulation of PLC-ζ isozyme activity: PLC-ζ is identified as 
sperm-specific PLC that is first identified from EST sequences of 
mouse and human testis. The molecular weight of PLC-ζ is 
about 70 kDa and is the smallest in size among other mamma-
lian PLC isozymes (35). Interestingly, injection of the recombi-
nant PLC-ζ protein generated Ca2＋ oscillation in the egg, 
caused by IP3 production in fertilizated egg. Primary sequences 
of PLC-ζ showed that it consists of the EF-hand domain, cata-
lytic X and Y domains, and the C2 domain. Comparative se-
quence analysis revealed that the catalytic X and Y domains 
bear about 64% of sequential amino acid similarity between 
PLC-ζ and PLC-δ1 (208). Also, five catalytic residues - His311, 
Glu341, Asp343, His356, and Glu390 at the catalytic X domain, are 
highly conserved between PLC-ζ and PLC-δ1, indicating that 
catalytic activation of PLC-ζ is similar to that of PLC-δ1. The de-
letion of the EF-hand domain of PLC-ζ abolished catalytic activ-
ity in vitro, suggesting that the EF-hand motif plays an im-
portant role in maintaining PLC activity (209). 
    Unlike other PLC isozymes, PLC-ζ lacks the PH domain, so 
it is not clear how PLC-ζ can target its membrane-bound sub-
strate, such as PIP2. It may be possible through the C2 domain. 
Deletion of the C2 domain from PLC-ζ reduced Ca2＋ sensi-
tivity only slightly, whereas PLC-ζ without the C2 domain does 
not cause Ca2＋ oscillation in mouse egg. This indicates that 
the C2 domain of PLC-ζ is essential for its function but dis-
pensable for Ca2＋ ion binding (210). 
Nuclear function of sperm-specific PLC-ζ isozyme: Originally, 
PLC-ζ protein has been discovered in soluble sperm extracts 
from mouse, hamsters and pigs. An earlier study showed that 
PLC-ζ protein was detected in both the soluble cytosolic frac-
tions of sperm extracts, as well as in the pellet of extracts that 
contained the sperm heads (35). When PLC-ζ is injected into 
an embryo at a later stage of development, it continues to un-
dergo nuclear sequestration. It suggests that in the case of 
PLC-ζ nuclear localization is required for egg activation and 
development. Indeed, PLC-ζ contains a nuclear localization 
signal, which promotes its accumulation in the pronuclei that 
form at the completion of meiosis II (208). 
Regulation of PLC-η isozyme activity: Recently, we and other 
groups have independently identified two PLC-η isozymes 
called PLC-η1 and PLC-η2, in human and mice (36-38). Like 
other PLC isozymes, primary sequences of PLC-η isozymes 
showed that the PH domain, four EF-hand motifs, catalytic X 
and Y domains, and the C2 domain. Primary sequences of 
PLC-η isozymes contain a long C-terminal region. However, 
BLAST analysis of the C-terminal extended region of PLC-η1 
and PLC-η2 revealed no homology with any other protein. 
Most PLC isozymes exist in the cytosol and translocate to the 
plasma membrane upon agonist-induced stimulation (128, 
211, 212). Surprisingly, extrinsic expression of PLC-η2 led to 
its predominant localization in the plasma membrane without 
extracelluar stimuli (38). When PH domain was deleted from 
PLC-η2, PLC- η2 was localized mainly in cytosol, but it was 
not detected in plasma membrane. This may suggest that the 
PH domain of PLC-η isozymes is essential for membrane 
localization. Both PLC-η1 and PLC-η2 isozymes exhibited 
Ca2＋-dependent PIP2 hydrolysis in vitro (36, 38). Co-ex-
pression of PLC-η2 with Gβγ resulted in enhanced PLC 
activity. We investigated whether PLC-η isozyme is activated 
by GPCR stimulation. We demonstrated that LPA- or PACAP 
can induce intracellular Ca2＋ release in a dose-dependent man-
ner in Neuro2A cells. However, LPA- or PACAP-induced 
Ca2＋release was dramatically reduced in PLC-η1 knock-down 
cell line (unpublished data), suggesting that PLC-η isozymes 
are activated through GPCR stimulation. 
    Both PLC-η isozymes are highly expressed in neuron-en-
riched regions in the brain, suggesting that PLC-η isozymes are 
particularly involved in the regulation of neural or neuroendo-
crine systems. However, physiological roles and cellular me-
chanisms of PLC-η isozymes remain to be studied.
Conclusion 
Recent identification of novel PLC isozymes and various splic-
ing variants can lead to a better understanding of complex sig-
naling networks. Isozyme-specific coupling to receptors is 
mediated by intracellular regulators such as G-proteins and 
adaptor molecules including NHERF2, and Shank 2. 
    Multiple splicing variants of PLC isozymes seem to contrib-
ute to functional diversities. In fact, PLC-β1 splicing led to the 
differential subcellular localization and functions of each splic-
ing variant. We found a new splicing variant of PLC-ε devoid of 
CDC25 domain and PLC-δ1 variant devoid of Y domain and C2 
domain. PLC-ε CDC25 domain functions as a GEF for Rap1A 
and helps persistent activation of PLC-ε during growth factor-de-
pendent activation process. The lack of this domain may lead to 
more transient activation of this splicing variant, which provides 
another functional diversity. The lack of catalytic Y domain of 
mouse PLC-δ1b suggests the possibility that this splicing variant 
may suppress PH domain-dependent activation of PLC-δ1a. 
Otherwise, PLC-δ1b may have a novel function similar to that of 
PRIP which regulates IP3-dependent Ca2＋release. The splicing 
variant specific functions of PLC isozymes need to be inves-
tigated to fully understand PLC-dependent signaling pathway. 
    The functional diversity of PLC is provided by their emerg-
ing novel molecular events. The lipase-independent functions 
of PLC-isozymes have been intensively revealed. PLC-γ1 has 
GEF activity in its SH3 domain and regulates PIKE or dynamin 
activity. Also, growth hormone-induced signaling is attenuated 
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by the complex formation mediated by PLC-γ1 SH2 and SH3 
domains. PLC-ε is a so-called dual enzyme since it has GEF ac-
tivity along with its PIP2 hydrolyzing activity. Knock-out ani-
mal studies revealed the various physiological functions of 
PLC isozymes. It is necessary to define more precisely the do-
main functions in the animal model in the future. Knock-in 
mice for PLC-γ1 tyrosine phosphorylation site mutants are cur-
rently being generated and this would unveil the function of 
PLC-γ1 tyrosine phosphorylation. 
    Much remains to be done in the investigation of the specific 
roles of newly identified members of PLC isozyme and their 
hierarchy in signal transduction networks. In addition, it is in-
dispensable to consider splicing variant specific functions of 
PLC isozymes. Advanced genetic and proteomic technology 
would provide us with answers to unsolved questions in this 
exciting field. 
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